Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
CA 2246560 C · Owner: Pfizer Products Inc. · Inventors: Welch, Willard Mckowan Jr.; Chenard, Bertrand Leo; Menniti, Frank Samuel
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal an effective amount of an antagonist of the AMPA receptor. Dopamine agonist therapy as referred to in, the present invention is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 3, 1998 and granted December 17, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 3, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 3, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.